Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVCN110101b
- Development stage
- Preclinical
- Lead developer
- Avicanna
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AVCN110101b is a preclinical-stage botanical cannabinoid formulation being developed by Avicanna. It is formulated using Avicanna's proprietary QUIX™ self-emulsifying drug delivery system (SEDDS) technology, which is designed to enhance the bioavailability, solubility, and stability of lipophilic cannabinoid compounds. Administered orally as a liquid, the formulation produces nano-sized cannabinoid droplets to support rapid onset and consistent absorption. The specific therapeutic indications and target cannabinoid receptors for AVCN110101b are currently to be determined.
- Other names
- Quix
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on AVCN110101b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVCN110101b.